Takeda Pharmaceutical announced new real-world data evaluating the comparative effectiveness of Entyvio (vedolizumab) and tumor necrosis factor-alpha (TNFalpha)-antagonist therapy in...
Takeda Pharmaceutical announced that an analysis based on pre-specified and post-hoc exploratory outcomes of GEMINI II and GEMINI III data...
Introduction: Hidradenitis suppurativa (HS) is a serious, debilitating, chronic inflammatory skin disease. Adalimumab is a fully human, immunoglobulin G1 monoclonal antibody specific for tumor necrosis factor-alpha...
Background: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease.
Background: Inflammatory cytokines such as tumor necrosis factor (TNF) have been implicated in the pathogenesis of psoriasis. We evaluated the safety and efficacy of etanercept, a TNF antagonist, for the treatment of plaque psoriasis.
Psoriasis is a chronic, immune-mediated, inflammatory dermatosis, affecting 2-3% of the US population.
Objectives: To assess the serum levels of proinflammatory cytokines TNF-α, IL-1β, IL-17A, IL-23 and high-sensitivity C-reactive protein (hs-CRP) in patients with HS and to evaluate the impact of treatment on cytokine levels.
Objective: To describe the clinical characteristics of TB in psoriasis patients treated with TNF antagonists.
Takeda Pharmaceuticals has announced that the European Commission (EC) has on 27 May 2014, granted Marketing Authorisation for Entyvio (vedolizumab),...
Novartis,, announced that the FDA has approved an intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).